Contribute Try STAT+ Today

Good morning, everyone, and how are you today? A spot of rain, and then some, is dousing the Pharmalot campus, but we are looking past the clouds. After all, the glass is always half full, yes? As George Burns used to say, ‘I look to the future, because that’s where I’m going to spend the rest of my life.’ So join us as we hoist a cup of stimulation to celebrate what lies ahead. And dig in to the list of interesting items below, too. Hope you have a splendid day and stay dry. …

The COVAX program sponsored by the World Health Organization raised another $2.4 billion from donors to fund more Covid vaccines for low- and middle-income countries, bringing the total pledged to $9.6 billion and exceeding the total funding targetHealth Policy Watch writes. But the 54 million more donations in vaccines that were also offered by wealthy nations is still fall far short of the 1 billion doses that the WHO and other global health leaders say are needed by September to fill immediate needs for fighting the pandemic.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.